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This study develops an original co-infection model in mice using Brucella melitensis, 
the most frequent cause of human brucellosis, and Trypanosoma brucei, the agent of 
African trypanosomiasis. Although the immunosuppressive effects of T. brucei in natural 
hosts and mice models are well established, we observed that the injection of T. brucei in 
mice chronically infected with B. melitensis induces a drastic reduction in the number of 
B. melitensis in the spleen, the main reservoir of the infection. Similar results are obtained 
with Brucella abortus- and Brucella suis-infected mice and B. melitensis-infected mice 
co-infected with Trypanosoma cruzi, demonstrating that this phenomenon is not due 
to antigenic cross-reactivity. Comparison of co-infected wild-type and genetically defi-
cient mice showed that Brucella elimination required functional IL-12p35/IFNγ signaling 
pathways and the presence of CD4+ T cells. However, the impact of wild type and an 
attenuated mutant of T. brucei on B. melitensis were similar, suggesting that a chronic 
intense inflammatory reaction is not required to eliminate B. melitensis. Finally, we also 
tested the impact of T. brucei infection on the course of Mycobacterium tuberculosis 
infection. Although T. brucei strongly increases the frequency of IFNγ+CD4+ T  cells, 
it does not ameliorate the control of M. tuberculosis infection, suggesting that it is not 
controlled by the same effector mechanisms as Brucella. Thus, whereas T. brucei infec-
tions are commonly viewed as immunosuppressive and pathogenic, our data suggest 
that these parasites can specifically affect the immune control of Brucella infection, with 
benefits for the host.
Keywords: infection control, Trypanosoma cruzi, Trypanosoma brucei brucei, Brucella melitensis, Brucella 
abortus, brucellosis, Mycobacterium tuberculosis
inTrODUcTiOn
In natural populations, individual resistance to infection is remarkably diverse. This has been linked 
to many factors [reviewed in Ref. (1)]. Among them, persistent infection can enhance the ability 
to control unrelated pathogens, a phenomenon termed the “Mackaness effect” in reference to the 
seminal work of Mackaness (2, 3) demonstrating cross-protection between L. monocytogenes, 
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Brucella abortus, and Mycobacterium tuberculosis infections in 
mice. Since this pioneering work, numerous examples of the 
Mackaness effect have been reported. For example, Herpes 
virus infection can provide beneficial protection against 
L. monocytogenes and Yersinia pestis (4). On the contrary, the 
lethal synergism between Influenza virus and certain bacteria, 
particularly Streptococcus pneumoniae, is well documented (5). 
As multiple unrelated infections in the same host are probably 
more common than single infections, it would be interesting 
to better understand the mechanisms underlying these cross-
protections or cross-aggravations.
Brucellae (alpha-proteobacteria) are facultative intracellular 
Gram-negative coccobacilli that infect mammals and cause 
brucellosis. Human brucellosis is a zoonotic infection trans-
mitted mainly through ingestion and inhalation (6). Without 
prolonged antibiotic treatment it causes a severe and debili-
tating chronic disease (7, 8). Despite significant progress, the 
incidence of human brucellosis remains very high in endemic 
areas, such as North Africa, the Mediterranean basin, and South 
America (9), and is considered to be largely underestimated 
(10). There is still no available safe and protective vaccine for 
humans (11, 12). Brucella melitensis is the most frequent cause 
of human brucellosis (8). Whole-body imaging of mice infected 
with high doses of bioluminescent B. melitensis has confirmed 
that the mouse infection model parallels human infection and 
identified major sites of bacterial growth and persistence, such 
as the spleen (13). Although the precise mechanisms of protec-
tive immunity against Brucella remain largely unknown, the 
role of IFNγ-producing CD4+ T  cells (Th1) in the control of 
Brucella growth in the spleen of infected mice is well estab-
lished (14–16).
Trypanosoma brucei is a strictly extracellular parasitic proto-
zoan hemoflagellate that causes African trypanosomiasis, also 
known as sleeping sickness in humans and nagana in animals. 
The mammalian bloodstream forms of T. brucei are remark-
able for their variant surface glycoprotein coats that undergo 
antigenic variation, thus enabling persistent escape from host 
adaptive immunity and chronic host infection [for a review, 
see Ref. (17)]. Wild-type C57BL/6 mice infected with T. brucei 
were characterized by an initial parasitemic surge inducing an 
intense IFNγ inflammatory response followed by subsequent 
cyclic parasitemic waves of smaller amplitude than the first peak. 
During chronic infection, T. brucei causes immunosuppression 
by various mechanisms. In particular, T. brucei induces the loss 
of various B-cell populations by apoptosis and thus abrogates the 
vaccine-induced protective response to a non-related pathogen 
(18). It also suppress the T-cell response by IFNγ/nitric oxide-
dependent and -independent pathways (19, 20).
Based on bibliographic data, we hypothesize that infection with 
T. brucei may affect the control of primary B. melitensis infection 
and the development of protective memory. To test these hypoth-
eses, we develop an original co-infection experimental model. 
B. melitensis-infected mice were infected with T. brucei at early 
and later time points. Surprisingly, co-infection induced a rapid 
and drastic reduction in the number of B. melitensis in the 
spleen and often its complete elimination. This phenomenon 
appeared to be dependent on IFNγ and CD4+ T cells.
MaTerials anD MeThODs
ethics statement
The procedures used in this study and the handling of the mice 
complied with current European legislation (directive 86/609/
EEC) and the corresponding Belgian law “Arrêté royal relatif à la 
protection des animaux d’expérience du 6 avril 2010 publié le 14 
mai 2010.” The Animal Welfare Committee of the Université de 
Namur (UNamur, Belgium) reviewed and approved the complete 
protocol (Permit Number: 12-188).
Mice and reagents
Wild-type C57BL/6 mice were acquired from Harlan (Bicester, 
UK). IL1R−/− C57BL/6, CD3ε−/− C57BL/6, and TCR-δ−/− 
C57BL/6 mice were purchased from The Jackson Laboratory 
(Bar Harbor, ME, USA). IL-12p35−/− C57BL/6 mice (21) were 
acquired from Dr. B. Ryffel (University of Orleans, France). 
TAP1−/− C57BL/6 mice (22) and MHCII−/− C57BL/6 mice (23) 
were acquired from Jörg Reimann (University of Ulm, Ulm, 
Germany). CD11c-DTR C57BL/6 mice were obtained from 
Dr. G. Holdenhove (Université Libre de Bruxelles, Belgium) 
and injected intraperitoneally (i.p.) with 500 ng of diphtheria 
toxin (DT) (Sigma) in PBS or with PBS alone (control). All 
wild-type and deficient mice used in this study were bred in the 
animal facility of the Gosselies campus of the Université Libre 
de Bruxelles (ULB, Belgium).
Brucella infection
We used wild-type B. melitensis 16M and strains stably 
expressing a rapidly maturing variant of the red fluorescent 
protein DsRed (mCherry-Br) (24), the mCherry protein 
(mCherry-Br), under the control of the strong Brucella spp. 
promoter, PsojA. Construction of the mCherry-Br strains 
has been described previously in detail (25). We also used 
B. abortus 2308 and Brucella suis 1330. All Brucella strains 
were grown in biosafety level III laboratory facilities. Cultures 
were grown overnight with shaking at 37°C in 2YT medium 
(Luria–Bertani broth with double quantity of yeast extract) 
and were washed twice in RPMI 1640 (Gibco Laboratories) 
(3,500 × g, 10 min) before inoculation of the mice. The mice 
were anesthetized with a cocktail of xylazine (9 mg/kg) and 
ketamine (36 mg/kg) in PBS before being inoculated intrana-
sally (i.n.) with 2 × 104 CFU of B. melitensis, B. abortus, and B. 
suis in 30 µl of PBS [described in Ref. (25)]. For the i.p. infec-
tion with B. melitensis, the mice received 2 × 104 CFU/500 μl 
of PBS. Control animals were inoculated with the same 
volume of PBS. The infectious doses were validated by plat-
ing serial dilutions of the inocula. The mice were sacrificed 
at the selected time after infection by cervical dislocation. 
Immediately after sacrifice, spleen cells were collected for 
bacterial count and flow cytometry analyses.
M. tuberculosis infection
C57BL/6 mice were infected with 50–100  CFU of virulent 
M. tuberculosis H37Rv using a nose-only inhalation 
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exposure system (CH Technologies, Inc., Westwood, NJ, USA). The 
M. tuberculosis H37Rv strain used was grown for 2 weeks as a 
surface pellicle on Sauton medium and stored frozen in aliquots 
at −80°C and is transformed with the reporter plasmid pSMT1, 
which expresses the Vibrio harveyi luxAB genes under the control 
of the BCG hsp60 promoter (26). The number of bioluminescent 
organisms [determined as relative light units (RLU)] in spleen 
homogenates was determined by a bioluminescence assay with a 
Modulus luminometer (Turner Biosystems) and 1% n-decanal in 
ethanol as a substrate. Data are expressed as log10 mRLU values 
per organ per mouse. All M. tuberculosis infections were per-
formed in a BSL3 facility at the Scientific Institute of Public Health 
(WIV-ISP) according to rules established by the ethics committee 
of the WIV-ISP and CODA-CERVA (permit 060202-02).
Trypanosoma infection
The pleomorphic AnTat 1.1E (EATRO 1125 stock) Trypanosoma 
brucei brucei (18) and a dominant-negative adenylate cyclase 
(DNac) mutant (27) were used in this study. T. brucei infection is 
characterized by multi-wave parasitemic development, in which 
every wave represents a parasite population of different antigenic 
type. DNac mutant parasitemia is considerably lower and dis-
plays no peak of infection (27). The mice were infected by i.p. 
injection of 5,000 parasites/mouse. Every 2–3 days, the number 
of parasites present in the blood was estimated using a count-
ing chamber and a light microscope. For T. brucei elimination, 
the mice were treated by i.p. injection of Berenil (diminazene 
aceturate, 14 mg/kg, Sigma-Aldrich) in 200 µl of distillated water 
(28). A parasite lysate was obtained by three freeze/thaw cycles 
as described in Ref. (29).
For Trypanosoma cruzi, we used the Tulahuen strain (geno-
type TcVI). The mice were infected by i.p. injection of 1,000 blood 
trypomastigotes as previously described (30). Blood parasitemia 
was evaluated regularly by microscopic examination.
antibiotic Treatment
Antibiotic treatment was administered to both immunized and 
control mice for 2 weeks. The oral treatment was a combination 
of rifampicin (12 mg/kg) and streptomycin (450 mg/kg) [adapted 
from Ref. (31)] prepared fresh daily and given in the drinking 
water. To ensure that the antibiotic treatment was effective, some 
mice from each group were sacrificed 1 week prior to the chal-
lenge, and the colony-forming unit counts were evaluated in the 
spleen.
Brucella counting
Spleens were crushed and transferred to PBS/0.1% X-100 Triton 
(Sigma-Aldrich). We performed successive serial dilutions in 
RPMI to obtain the most accurate bacterial count and plated 
them onto 2YT medium. The colony-forming units were counted 
after 5 days of culture at 37°C.
enzyme-linked immunosorbent assay 
(elisa)
Brucella-specific murine IgM and IgG isotypes were determined 
by ELISA. Polystyrene plates (Nunc 269620) were coated with 
heat-killed B. melitensis (107  CFU/ml). After incubation over-
night at 4°C, the plates were blocked for 2 h at room temperature 
(RT) with 200  µl of PBS-3.65% casein. The plates were then 
incubated overnight at 4°C with 50 µl of serial dilutions of the 
serum in PBS-3.5% casein. The sera of unimmunized mice were 
used as the negative control. After four washes with PBS, isotype-
specific goat anti-mouse horseradish peroxidase conjugates were 
added (50 μl/well) at appropriate dilutions (hIgM from Sigma; 
LO-MG2a-9 HRPO). The plates were incubated for 2 h at RT and 
washed four times in PBS before adding 100 µl of substrate solu-
tion (BD OptEiA) to each well. After 10 min of incubation at RT 
in the dark, the enzyme reaction was stopped by adding 25 μl/well 
of 2 N H2SO4, and absorbance was measured at 450 nm.
cytofluorometric analysis
As described previously (16), spleens were harvested, cut into 
small pieces and incubated for 30  min at 37°C with a mix of 
DNAse I fraction IX (Sigma-Aldrich) (100 µg/ml) and 1.6 mg/ml 
of collagenase (400 M and l U/ml). The spleen cells were washed 
and filtered, and then incubated with saturating doses of puri-
fied 2.4G2 (anti-mouse Fc receptor, ATCC) in 200 µl PBS 0.2% 
BSA 0.02% NaN3 (FACS buffer) for 20  min at 4°C to prevent 
antibody binding to the Fc receptor. Various fluorescent mAb 
combinations in FACS buffer were used to stain 3–5  ×  106 
cells. We acquired the following mAbs from BD Biosciences: 
phycoerythrin (PE)-coupled HL3 (anti-CD11c), FITC-coupled 
145-2C11 (anti-CD3ε), FITC-coupled M1/70 (anti-CD11b), 
PE-coupled RM4-5 (anti-CD4), allophycocyanin (APC)-coupled 
1-A/1-E (anti-MHCII), and APC-coupled XMG1.2 (anti-IFNγ). 
Purified M-19 (rabbit polyclonal IgG anti-NOS2; Santa Cruz 
Biotechnology) was stained with Alexa Fluor 647 goat anti-rabbit 
(Molecular Probes). The cells were analyzed on a FACScalibur 
cytofluorometer. Dead cells and debris were eliminated from the 
analysis according to size and scatter.
statistical analysis
We used a (Wilcoxon–)Mann–Whitney test provided by the 
GraphPad Prism software to statistically analyze our results. 
Each group of deficient mice was compared to the wild-type mice. 
We also compared each group with each other and displayed 
the results when required. Values of p < 0.05 were considered to 
represent a significant difference. *, **, and *** denote p < 0.05, 
p < 0.01, and p < 0.001, respectively.
resUlTs
B. melitensis Persists in cD11c+ reservoir 
cells in the spleen and is able to resist  
to Protective Memory immune response
The identification of reservoir cells allowing for the persistence 
of Brucella in vivo constitutes a crucial step in our understand-
ing of how Brucella escapes the immune system. Following i.n. 
administration of 2 × 104 CFU of B. melitensis, we have shown 
previously (16) that the bacteria persist in the lungs up to 12 days 
postinfection and the spleen and liver are colonized starting 
5  days postinfection. At 28  days postinfection, B. melitensis is 
FigUre 1 | Brucella persisted in CD11c+ reservoir cells in the spleen of chronically infected wild-type C57BL/6 mice. Wild-type and DTR-CD11c C57BL/6 mice 
received i.n. 2 × 104 CFU of mCherry-Brucella melitensis in PBS or PBS alone (control group). 26 or 48 days later, the mice received 500 ng of diphtheria toxin by 
i.p. route in 500 µl of PBS or PBS alone. Two days later (28 or 50 days post Brucella infection), the mice were sacrificed, and the spleens were harvested. (a) Flow 
cytometry analysis of CD11c and MHCII expression on spleen cells. The data show a representative dot plot for individual mice. (B) The data represent the number 
of colony-forming units per gram of spleen for each group of mice at the indicated time of infection. Gray bars represent the median. n denotes the number of mice 
used for each group (*p < 0.05, **p < 0.01). These results are representative of at least two independent experiments.
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only detected in the spleen by CFU analysis. At that time, it is not 
detected in the lungs, liver, brain, ovaries, heart, thigh muscle, 
and tissues of the tail (data not shown). Microscopic analysis 
has demonstrated that during the chronic phase of infection 
of highly susceptible IL-12p40−/− BALB/c mice, B. melitensis 
resides in specific reservoir cells expressing a particular pheno-
type (CD11c+CD11b−CD205+arginase+) (32). Due to the low 
number of B. melitensis persisting in the spleen of resistant mice 
(103–104 CFU/spleen, less than 1 infected cell per 104 spleen cells), 
in situ microscopic analysis of the phenotype of the infected cells 
is not possible. To solve this problem, we chose to use CD11c-DTR 
C57BL/6 mice that express the DT receptor under the control of 
the CD11c promoter. As previously reported (33), injection of DT 
in DTR mice induced the transitory elimination of CD11c+ cells.
To determine if the B. melitensis reservoir cells express 
CD11c, DTR mice infected for 26 or 48 days with 2 × 104 CFU 
of mCherry-B. melitensis received 500 ng of DT in 500 µl of PBS 
or PBS alone (control group). Two days later, the mice were sac-
rificed and the spleens were harvested. Flow cytometry analysis 
showed that DT induced a depletion of CD11chigh cells in control 
and Brucella-infected DTR mice but not in wild-type mice 
(Figure 1A). Elimination of the CD11c+ cells in DTR mice led 
to a drastic reduction in the number of bacteria compared to the 
mice treated with PBS alone (Figure 1B). Note that, as expected, 
we observed no significant impact of DT administration on the 
control of Brucella infection in wild-type C57BL/6 mice (Figure 
S1 in Supplementary Material). These results suggest that Brucella 
persists in CD11c+ reservoir cells in wild-type C57BL/6 mice.
We have previously shown that i.p. (31) or i.n. (16) Brucella 
infection in wild-type C57BL/6 mice induces a protective memory 
T cell response able to control and completely eliminate a second-
ary Brucella infection in a majority of mice. To determine whether 
FigUre 2 | Brucella reservoir cells were resistant to the protective memory 
response. Wild-type C57BL/6 mice were infected i.n. with 2 × 104 CFU of 
wild-type Brucella melitensis and challenged i.p. or i.n. with 2 × 104 CFU of 
mCherry-B. melitensis. The mice were euthanized at the selected time, and 
the spleen was harvested, as described in panel (a). The data in panels 
(B,c) represent the number of colony-forming units per gram of spleen for 
each group of mice. Gray bars represent the median. n denotes the number 
of mice used for each group (***p < 0.001). These results are representative 
of at least two independent experiments.
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the activation of memory T  cells during a secondary infection 
is able to eliminate Brucella from the first infection persisting 
in splenic reservoir cells, we compared the CFU levels of non-
fluorescent (wild-type) B. melitensis and mCherry-B. melitensis in 
the spleens of five groups of mice. The precise treatment of each 
group is described in detail in Figure 2A. As expected, both the 
i.p. and the i.n. mCherry Brucella challenge was controlled well 
in mice chronically infected with wild-type Brucella (Figure 2B), 
thus confirming the presence of a protective memory response 
in these mice. In striking contrast, the CFU levels of wild-type 
Brucella were similar in unchallenged mice and in the i.p. and 
i.n. challenged groups (Figure 2C). This demonstrates that the 
memory response is able to eliminate the challenge strain but not 
the Brucella strain that has settled in the reservoir cells. To the 
best of our knowledge, this observation has never been reported 
before and suggests that the reservoir cells protect Brucella against 
the Brucella-specific memory response.
T. brucei infection reduces the number of 
Brucella Persisting in the spleen
Co-infection could positively or negatively affect the control of 
ongoing infection [reviewed in Ref. (1)]. Wild-type C57BL/6 mice 
were infected i.n. with PBS or 2 × 104 CFU of mCherry-B. meliten-
sis and then received an i.p. injection of PBS or 5,000 parasites at 
7 or 45 days post Brucella infection (as indicated in Figure 3A). 
At the selected time point following T. brucei infection, the 
number of parasites was measured in the blood (Figure 3B). No 
significant impact of Brucella infection on the course of T. brucei 
was detected. In the same experiment, at a selected time point 
following Brucella infection, the mice were sacrificed, the spleens 
were harvested, and the Brucella CFUs in the spleen were counted 
by plating (Figures 3C,D). Our results showed that both early (day 
7, Figure 3C) and late (day 45, Figure 3D) infection with T. brucei 
induced a rapid decrease in the CFU count of B. melitensis in the 
spleen. At 5 days post T. brucei infection (Figure 3C), the CFU 
level was already decreased by >1 log in the co-infected mice com-
pared to the mice infected with B. melitensis alone. Twenty-one 
days following early and late T. brucei infection (Figures 3C,D), 
the CFU level appeared to be reduced by approximately 3 log, and 
the B. melitensis CFU count was below the detection threshold 
(10 CFU/spleen) in the majority of the co-infected mice. Similar 
results were obtained in the i.p. model of B. melitensis infection 
(Figure S2 in Supplementary Material). These results suggest that 
the immune response induced by T. brucei infection is able to 
eliminate Brucella in its reservoir cells. It is important to remark 
that this effect is not due to depletion of the entire CD11c+ spleen 
cell population, like in CD11c-DTR mice treated with DT, as the 
frequency of CD11c+MHCII+ cells is not significantly reduced in 
the spleen of T. brucei co-infected mice compared to the spleen 
of Brucella-infected mice (Figure S3 in Supplementary Material).
To determine whether the elimination of B. melitensis 
observed after T. brucei infection could be the consequence of 
antigenic cross-reactivity, we tested whether T. brucei can affect 
the growth of two other Brucella species able to infect humans, 
 B. abortus and B. suis, in the spleen (Figures 4A,B), and whether i.p. 
T. cruzi infection also reduces the level of B. melitensis 
(Figure 4C). T. cruzi is an intracellular parasite displaying differ-
ent infection kinetics and does not share an antigen with T. brucei. 
We observed that T. brucei infection leads to a 10-fold reduction of 
B. abortus and B. suis CFUs in the spleen and that T. cruzi infec-
tion also induces a drastic reduction of B. melitensis in the spleen 
of infected mice. These results strongly suggest that elimination 
of Brucella following Trypanosoma infection is not due to shared 
antigens between the pathogens.
FigUre 3 | Trypanosoma brucei co-infection strongly reduced the CFU level of Brucella melitensis in the spleen. Wild-type C57BL/6 mice were infected i.n. with 
PBS or 2 × 104 CFU of mCherry-B. melitensis and, at 7 or 45 days postinfection, received an i.p. injection of PBS or 5,000 T. brucei or PBS alone, as described in 
panel (a). The data in panel (B) represent the number of T. brucei per milliliters of blood. The data in panels (c,D) represent the number of colony-forming units per 
gram of spleen. Note that, to avoid a possible effect of repeated blood sampling, mice that were bled to measure the number of parasites in the blood were not 
used to measure the number of Brucella CFUs in the spleen. Gray bars represent the median. n denotes the number of mice used for each group (**p < 0.01, 
***p < 0.001). These results are representative of at least two independent experiments.
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elimination of Brucella by T. brucei 
requires Functional il-12/iFnγ signaling 
Pathways
IFNγ-producing CD4+ T cells are key players in the protective 
immune response against B. melitensis (16). When comparing 
the impact of T. brucei infection on B. melitensis in wild-type 
and various deficient mice, we observed that T. brucei-induced 
elimination of B. melitensis is strongly reduced in CD3−/− (1-fold 
reduction of colony-forming unit), MHCII−/− (6-fold), and 
IL-12p35−/− mice (8-fold) but not in TAP1−/− (767-fold), TCR-
δ−/− (1,935-fold), and IL1R−/− mice (418-fold) (Figure 5A) when 
FigUre 4 | Impact of Trypanosoma brucei co-infection on Brucella suis and Brucella abortus infection and impact of Trypanosoma cruzi on Brucella melitensis 
infection. Wild-type C57BL/6 mice were infected i.n. with 2 × 104 CFU of B. abortus (a) or B. suis (B) and, at 7 days postinfection, received an i.p. injection of 5,000 
T. brucei in 200 µl of PBS or PBS alone. (c) Wild-type C57BL/6 mice were infected i.n. with 2 × 104 CFU of mCherry-B. melitensis and, at 7 days postinfection, 
received an i.p. injection of 1,000 T. cruzi in 200 µl of PBS or PBS alone. The mice were euthanized at 28 days post Brucella infection, and the spleen was 
harvested. The data represent the number of colony-forming units per gram of spleen. Gray bars represent the median. n denotes the number of mice used for each 
group. These results are representative of at least two independent experiments (***p < 0.001).
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compared to wild-type mice (503-fold). These results suggest 
that the mechanism underlying the elimination of B. melitensis 
by T. brucei is indeed dependent on the host adaptive immune 
response and partially requires functional IL-12/IFNγ signaling 
pathways and CD4+ T cells. Elimination of B. melitensis follow-
ing co-infection with T. cruzi is also dependent on IL-12 (Figure 
S2 in Supplementary Material). Note that depletion of CD4+ or 
CD8+ T cells by injection of depleting antibodies to confirm the 
data obtain with MHCII−/− and TAP1−/− mice is not feasible in 
this model. Indeed, CD11c+ cells constitute a potential Brucella 
reservoir cells, and it is well known that some subpopulations of 
splenic CD11c+ dendritic cells express CD4 or CD8 receptors.
As nitric oxide produced by iNOS/NOS2 is widely known 
to be produced in response to IFNγ in B. melitensis (34) and 
T. brucei (35) models and to negatively affect B. melitensis growth 
in the spleen (34), we analyzed by flow cytometry the frequency 
of IFNγ- and iNOS-producing cells in the spleen of wild-type and 
various deficient mice infected with B. melitensis, T. brucei or co-
infected with both pathogens. Our results showed that T. brucei 
induced a strong increase in the frequency of IFNγ (Figure 5B) 
and iNOS-producing cells (Figure  5C) in the spleen. IFNγ is 
mainly produced by CD3+CD4+ T  cells and iNOS is produced 
by CD11b+ cells (data not shown). As expected, the absence of 
IL-12p35 significantly reduces the frequency of IFNγ+ and iNOS+ 
cells. Interestingly, there was no significant difference between 
the frequency of IFNγ and iNOS-producing cells in the spleen of 
TAP1−/− (deficient in CD8+ T cells) and MHCII−/− (deficient in 
CD4+ T cells) mice, demonstrating that the absence of T. brucei-
induced B. melitensis control in MHCII−/− mice is indeed due to 
the absence of CD4+ T cells and not only to the lack of IL-12/IFNγ 
signaling pathways.
T. brucei infection Does not affect  
the course of M. tuberculosis infection  
in Mice
Brucella melitensis and M. tuberculosis are both facultative 
intracellular bacteria able to chronically colonize the spleen 
of infected mice. It is clearly established that IFNγ production 
(36, 37) and activated CD4+ T cells (38) participate in the protec-
tive immune response against M. tuberculosis in mice, suggesting 
that bystander activation of these effector mechanisms by T. bru-
cei could promote the control of M. tuberculosis. Thus, we tested 
the impact of i.p. T. brucei infection on the course of C57BL/6 
mice previously infected by aerosol with M. tuberculosis, as 
described in Figure 6A. Surprisingly, we observed that, despite 
the enhanced frequency of IFNγ-producing cells in the spleen of 
co-infected mice (Figure 6B), T. brucei did not affect M. tuber-
culosis infection in the spleen either earlier (36 days, Figure 6C) 
or later (91  days, Figure  6D). This result demonstrates that 
T. brucei infection specifically impacts B. melitensis infection and 
that these effects cannot be generalized to all other intracellular 
bacterial infections.
an attenuated T. brucei Mutant is  
able to reduce Brucella infection
Our previous experiments showed that T. brucei induces a strong 
inflammatory response mediated by IFNγ+CD4+ T cells in infected 
FigUre 5 | Elimination of Brucella during Trypanosoma brucei infection required IL-12 and CD4+ T cells. (a) Wild-type and various genetically deficient C57BL/6 
mice were infected i.n. with 2 × 104 CFU of mCherry-Brucella melitensis and, at 7 days postinfection, received an i.p. injection of 5,000 T. brucei in 200 µl of PBS 
(co-infection group) or PBS alone (B. melitensis group). The mice were euthanized at 28 days post Brucella infection, and the spleen was harvested (a). The data 
represent the number of colony-forming units per gram of spleen. Gray bars represent the median. n denotes the number of mice used for each group. (B,c) The 
data represent the frequency of IFNγ- and iNOS-producing cells in the spleen as determined by flow cytometry analysis. The control (cont) group consisted of naive 
mice receiving PBS only (**p < 0.01, ***p < 0.001). These results are representative of at least two independent experiments.
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mice and that this response is indispensable to the reduction of 
Brucella infection in co-infected mice. To determine whether 
the intensity and duration of the IFNγ-mediated response are 
key parameters, we compared a wild-type T. brucei and a DNac 
T. brucei mutant (27), as described in Figure 7A. Infection with 
the DNac mutant induced a considerably lower parasitemia and 
a smaller inflammatory immune response (27). We observed that 
both wild-type and DNac T. brucei induced similar elimination 
of B. melitensis in co-infected mice (Figure 7B). The kinetics of 
elimination were very similar, except for the early time point of 
co-infection (day 12). The slower impact of the DNac mutant on 
Brucella could be due to the fact that it induces IFNγ less rapidly 
in spleen as demonstrated by the reduced frequency of IFNγ-
producing cells in the spleen of DNac T. brucei-infected mice early 
in co-infection compared to wild-type T. brucei-infected mice 
(Figures 7C,D). Like for wild-type T. brucei, Brucella elimination 
by DNac T. brucei was impaired in IL-12p35−/− mice (Figure S4 in 
Supplementary Material). On the whole, these results suggest that 
even lower persistence of parasite associated with lower levels of 
IFNγ is able to mediate B. melitensis elimination. However, live 
parasite seems to be required as we failed, in the same experiment, 
to reduce B. melitensis infection by three repeated injection (once 
per week) of a lysate of T. brucei (Figure S5 in Supplementary 
Material). The lysate has been realized, approximately, from a 
number of cultivated parasites corresponding to the number of 
parasites detected in the blood of infected mice at the peak of 
infection.
Transient T. brucei infection Does not 
alter Development of the Protective 
Memory response against B. melitensis
Trypanosoma brucei infection has been described to deeply 
affect the protective humoral immune memory against unrelated 
pathogens (18). Thus, we planned to analyze the impact of 
T. brucei infection on the specific protective immune memory 
FigUre 6 | Impact of Trypanosoma brucei co-infection on the course of 
Mycobacterium tuberculosis infection in mice. Wild-type C57BL/6 mice were 
infected by aerosol with 5 × 103 CFU of M. tuberculosis and, at 15 or 
80 days postinfection, received an i.p. injection of 5,000 T. brucei in 200 µl of 
PBS (M. tuberculosis/T. brucei group) or PBS alone (M. tuberculosis group). 
The mice were euthanatized at the selected time post M. tuberculosis 
infection, and the spleen was harvested, as described in panels (a,B). The 
data represent the frequency of IFNγ-producing cells in the spleen as 
determined by flow cytometry analysis. (c,D) The data represent the number 
of mRLU/g of spleen. Gray bars represent the median. n denotes the number 
of mice used for each group (***p < 0.001). These results are representative 
of at least two independent experiments.
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in Figure 8A. Both groups of mice were treated with Berenil, an 
antiparasitic drug (28). After a resting period, the mice were i.p. 
challenged with mCherry B. melitensis. A group of naive mice, 
treated with antibiotic and Berenil, was also i.p. infected with 
mCherry B. melitensis and was used as the internal control (pri Br 
cont group). Surprisingly, T. brucei infection did not reduce the 
ability of B. melitensis immunized mice to control an i.p. Brucella 
challenge in the blood (Figure  8B) or the spleen (Figure  8C), 
despite a drastic reduction in the frequency of B cells (Figure S6A 
in Supplementary Material) and Brucella-specific IgM and IgG2a 
(Figures S6B,C in Supplementary Material). The same experi-
ment in the B. melitensis i.n. infection model (i.n. infection and 
i.n. challenge with B. melitensis) gave similar results (Figure 8D). 
Thus, although T. brucei infection reduces the specific humoral 
response against B. melitensis, it does not impair the protective 
memory response controlling secondary B. melitensis infection 
in either the i.p. or i.n. infection model.
DiscUssiOn
Immunology arose from the will and the need to ameliorate 
vaccination. During the 20th century, the molecular biology 
revolution led immunologists to develop highly reductionist 
experimental models, far removed from reality. For many years, 
the most studied immunological models were based on the injec-
tion of proteins combined with adjuvants. Much of our under-
standing of how the immune system works derives from studies 
of these models. We must not forget that our perception of reality 
results from the experimental model in which we study it. It may 
be time to remember that the first successful vaccination actually 
derives from a cross-reaction between smallpox and the cowpox 
virus and that multiple unrelated infections in the same host are 
probably more common than single mono-species infections. 
The impact of past or chronic unrelated infections on the ability 
of the host to control infection is well documented [reviewed in 
Ref. (1)], but the mechanisms remain largely unknown. In this 
study, we developed an original experimental model of co-
infection to study the impact of T. brucei infection on the course 
of chronic infection with B. melitensis in mice.
Over the course of evolution, Brucella has acquired specific 
stealth strategies that allow it to interfere with its recognition 
by the immune system and neutralize immune effector mecha-
nisms. For example, after phagocytosis, Brucella controls the 
intracellular trafficking of its vacuole to avoid degradation by 
phagolysosomes [reviewed in Ref. (39)]. We have shown previ-
ously in a mice model that following i.p. (15) or i.n. infection 
(16) the spleen is stably and durably colonized by Brucella and 
constitutes one of the major reservoirs of the infection. In the 
spleen of highly susceptible IL-12p40−/− BALB/c mice, Brucella 
persists within specific CD11c+CD205+arginase1+ myeloid cells 
displaying high levels of lipids (32). In this study using CD11c-
DTR C57BL/6 mice, we demonstrated that specific elimination 
of CD11c+ cells reduced colony-forming unit counts of Brucella 
in the spleen, suggesting that Brucella survives in CD11c+ res-
ervoir cells in resistant C57BL/6 mice. Our results showed that 
these reservoir cells constitute a niche that hides Brucella from 
the primary immune response and even against the protective 
following B. melitensis infection. We have shown previously that 
humoral immunity-mediated control of secondary infection 
with B. melitensis is dependent on the route of infection. In the 
i.p. model, bacteria disseminate by the blood, and the humoral 
immune response is indispensable to efficiently control second-
ary infection (31). In contrast, bacteria disseminate slowly after 
i.n. infection, are undetectable in the blood, and the absence of 
B  cells does not affect the control of secondary infection (16). 
We therefore chose to analyze the effects of T. brucei in both i.p. 
and i.n. B. melitensis infection models.
Mice were i.p. infected with wild-type B. melitensis for 28 days, 
treated with antibiotic and then infected (Sec Br/T. brucei 
group) or not (Sec Br cont group) with T. brucei, as described 
FigUre 7 | Attenuated dominant-negative adenylate cyclase (DNac) mutant of Trypanosoma brucei induced the elimination of Brucella. Wild-type C57BL/6 mice 
were infected i.n. with 2 × 104 CFU of mCherry-Brucella melitensis and, at 7 days postinfection, received an i.p. injection of 5,000 wild-type T. brucei or attenuated 
DNac mutant of T. brucei in 200 µl of PBS or PBS alone. The mice were euthanized at 12, 19, and 28 days post Brucella infection and the spleen was harvested, as 
described in panel (a,B). The data represent the number of colony-forming units per gram of spleen. Gray bars represent the median. n denotes the number of mice 
used for each group. (c,D) The data represent the mean of the frequency of IFNγ-producing cells (c) and CD3+CD4+ IFNγ-producing cells (D) in the spleen from 
five individual spleens as determined by flow cytometry analysis for each group. n denotes the number of mice used for each group (*p < 0.05, **p < 0.01, 
***p < 0.001). These results are representative of at least two independent experiments.
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Brucella-specific memory response. Indeed, in mice chronically 
infected since 45 days with wild-type B. melitensis, a new infec-
tion with mCherry B. melitensis challenge strain is completely 
neutralized. But this specific memory response appears to be 
unable to eradicate the established wild-type Brucella strain. 
Thus, during chronic infection phase, Brucella appears to be 
extremely well equipped to escape the IFNγ-mediated protective 
immune response (16) and persist in the host. It is therefore 
really surprising and unexpected, in view of the well documented 
immunosuppressive effects of many trypanosomes (40), that 
both T. brucei and T. cruzi infection lead to an almost 2–3 log 
reduction of the B. melitensis load in the spleen of co-infected mice. 
T. brucei is known to suppress both the T-cell (19, 20) and B-cell 
(18) response in mice. T. cruzi infection reduces the humoral 
immune response against sheep erythrocytes in humans (41). 
To the best of our knowledge, neither T. brucei nor T. cruzi infec-
tion has been previously associated with an increased response to 
unrelated pathogens. A study by Lowry et al. (42) compared the 
course of B. abortus S19 in control and Trypanosoma musculi-
infected mice. In striking contrast with our results, Lowry et al. 
showed that T. musculi favor B. abortus infection by suppressing 
the IFNγ response. The difference between Lowry’s co-infection 
FigUre 8 | Trypanosoma brucei co-infection did not affect the protective memory against Brucella melitensis. As described in panel (a), wild-type C57BL/6 mice 
were infected i.p. or i.n. with 2 × 104 CFU of wild-type B. melitensis and treated with antibiotic at 28 days postinfection for 15 days. At 65 days, the mice received an 
i.p. injection of 5,000 T. brucei in 200 µl of PBS (Sec Br/T. brucei group) or PBS alone (Sec Br cont group) were treated with Berenil at 86 days and were challenged 
at 102 days with i.p. or i.n. injection of 2 × 104 CFU of mCherry-B. melitensis. The pri Br cont group received only PBS, antibiotic, and Berenil until the Brucella 
challenge. (B,c) i.p. model: the data represent the number of colony-forming units per milliliter of blood or colony-forming units per gram of spleen at the selected 
time post challenge, as indicated. (D) i.n. model: the data represent the number of colony-forming units per gram of spleen. Gray bars represent the median.  
n denotes the number of mice used for each group (**p < 0.01, ***p < 0.001). These results are representative of at least two independent experiments.
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model and our model may be due to the different timing of 
co-infection and Trypanosoma species used. Especially, T. brucei 
and T. cruzi induce a greater inflammatory response in mice than 
does T. musculi.
The fact that two species of Trypanosoma displaying com-
pletely different antigens, infectious cycles and dynamics are 
both able to favor the elimination of three different species of 
Brucella (melitensis, suis, and abortus) suggests that the underly-
ing mechanism has very little chance of being based on antigenic 
cross-reactivity. The comparison of various deficient mice has 
demonstrated that CD4+ T  cells, but not CD8+ T  cells or γδ+ 
T cells, are indispensable to Brucella elimination, and thus that 
the immune response is directly implicated in this phenomenon. 
We also observed that functional IL-12p35/IFNγ signaling 
pathways are required. Taken together, these results suggest that 
the strong inflammatory IFNγ-mediated response induced by 
T. brucei and T. cruzi infection is responsible for the elimina-
tion of Brucella. Interestingly, in the absence of CD4+ T  cells 
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(MHCII−/− mice), T. brucei induced a strong IFNγ response 
mediated by CD8+ T cells but was not able to reduce the level 
of Brucella persistence in the spleen, thus suggesting that IFNγ 
production is necessary but not sufficient to eliminate Brucella 
and that CD4+ T cells are key actors in this process. Infection with 
a strongly attenuated T. brucei mutant, but not repeated injection 
of a T. brucei lysate, was able to eliminate Brucella in the spleen, 
suggesting that the level of inflammation is not a limiting factor 
but that a living parasite is required. B cell deficient mice have 
been shown to display enhanced control of Brucella infection 
(43), and B cells have been reported to act as reservoir cells for 
Brucella in the spleen (44). As T. brucei is well known to induce 
B cell apoptosis (18), we cannot exclude that Brucella elimination 
by T. brucei could in part be a consequence of B cell depletion by 
T. brucei. However, T. brucei infection does not completely elimi-
nate B cells in our model (Figure S5 in Supplementary Material). 
In addition, the colony-forming unit count reduction induced by 
T. brucei is already observed after 5 days, while no impact on the 
frequency of B  cells in the spleen is detected at the same time 
[data not shown and Ref. (18)].
The fact that T. brucei infection affects B. melitensis, B. suis, and 
B. abortus, but not early or late phases of M. tuberculosis infection 
in the spleen, demonstrates that the mechanism implicated is 
specific to Brucella species but is not effective against all intra-
cellular bacterial infections. However, the results obtained with 
M. tuberculosis are unexpected given the strong available evidence 
that a deficiency of IFNγ responses is associated with increased 
susceptibility to M. tuberculosis and non-tuberculous mycobacte-
rial infections in animal models and humans (45, 46). In addition, 
Sakai et al. (47) recently nicely confirmed the protective role of 
IFNγ-producing CD4+ T in the control of extra-pulmonary 
M. tuberculosis infection. In our experimental model, we observed 
decreased IFNγ production in vitro in response to known MHC 
class II epitopes of M. tuberculosis antigens in splenocytes iso-
lated from mice co-infected with M. tuberculosis and T. brucei 
compared to the responses measured in splenocytes from mice 
infected with M. tuberculosis (data not shown). This suggests 
that co-infection with T. brucei could have a negative impact 
on IFNγ responses by M. tuberculosis specific CD4+ T cells and 
that direct recognition of infected cells by specific CD4+ T cells 
rather than the presence of high levels of IFNγ may be essential to 
restricting the growth of M. tuberculosis. In addition, we cannot 
exclude that the beneficial impact of IFNγ production may be 
counterbalanced by some immunosuppressive effects associated 
to T. brucei infections.
Finally, as T. brucei is especially known for its ability to sup-
press vaccine-induced protective humoral memory (18), we 
tested the ability of T. brucei to neutralize Brucella-induced pro-
tective memory in i.p. and i.n. infection models. As expected, we 
observed a significant decrease in the B cell count in the spleen and 
a reduction of Brucella-specific IgM and IgG2a levels in the serum 
of co-infected mice compared to control Brucella-infected mice. 
Interestingly, similar results have been reported in cattle infected 
with either Trypanosoma congolense or Trypanosoma vivax that 
display suppressed humoral immune responses to attenuated 
B. abortus injected subcutaneously (48). Despite this reduction 
of the Brucella-specific humoral response, we did not observe a 
reduced ability of the humoral response to neutralize Brucella in 
the blood or to impair Brucella persistence in the spleen.
On the whole, our results show that both T. brucei and 
T. cruzi infection are able to positively improve the immune 
control of Brucella infection in the spleen. This demonstrates that 
non-antigen specific effector mechanisms could be more efficient 
at eliminating stealth pathogens like Brucella than antigen specific 
immune effectors. This finding opens up new perspectives for 
research on brucellosis as well as for other stealth pathogens. This 
co-infection model also offers a unique opportunity to identify the 
effector mechanisms expressed by CD4+ T cells involved in the 
elimination of Brucella reservoir cells and could be further used 
to discover new therapeutic strategies for brucellosis without anti-
biotic treatment. As mice are not a natural host for B. melitensis 
and T. brucei, extrapolation of these results to natural hosts must 
be done carefully. However, the geographic distribution of these 
pathogens is largely overlapping, and all of them infect cattle and 
humans. Thus, co-infection of the natural host with Brucella and 
Trypanosoma, although not documented, should not be uncom-
mon, and these effects deserve to be studied in nature.
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